文献速递临床试验与 GCP真实世界研究与卫生经济

立体定向体部放疗对比中度大分割调强放疗治疗中危局限期前列腺癌:一项随机临床试验

Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

NRG-GU005是一项国际开放标签3期随机试验,纳入698例中危局限期前列腺癌患者,比较SBRT与MH-IMRT。2年时泌尿刺激/梗阻症状无显著差异,SBRT在肠道生活质量、泌尿失禁及性功能方面更优,但3年无病生存率MH-IMRT组更高。

要点

  • SBRT组2年肠道领域MCID发生率显著低于MH-IMRT组(34.9% vs 43.8%,P=.03)。
  • SBRT组3+4级泌尿生殖不良事件更少(0.6% vs 2.5%,P=.04)。
  • 3年DFS MH-IMRT组为92.1%(95%CI 88.9%-95.2%),SBRT组为88.6%(95%CI 85.2%-92.1%)。

核心结论

  • SBRT使用适度剂量处方改善了多个生活质量领域,但在无病生存方面未优于MH-IMRT。
  • SBRT组与MH-IMRT组相比,PSA失败率未显著改善。

研究设计与样本

  • 研究纳入亚洲、加拿大、欧洲和美国136个中心的698例患者,随机1:1接受SBRT(36.25 Gy/5次,n=353)或MH-IMRT(70 Gy/28次或60 Gy/20次,n=345)。
  • 入组标准为局限期前列腺癌,临床分期T1-T2b且Gleason 3+4(分级组2)且PSA<20 ng/mL,或Gleason 3+3(分级组1)且PSA 10-20 ng/mL。
  • 中位年龄68岁,中位随访3.2年(范围0-6.5年)。

主要发现

  • 2年时泌尿刺激/梗阻领域MCID发生率无显著差异(35.4% vs 33.7%,P=.68)。
  • SBRT组2年肠道领域MCID发生率显著低于MH-IMRT组(34.9% vs 43.8%,P=.03)。
  • SBRT组3+4级泌尿生殖不良事件发生率显著低于MH-IMRT组(0.6% vs 2.5%,P=.04)。
  • 治疗后1年和2年泌尿失禁及治疗后1年性功能 favoring SBRT。
  • 3年DFS MH-IMRT组为92.1%(95%CI 88.9%-95.2%),SBRT组为88.6%(95%CI 85.2%-92.1%)(单侧log-rank P<.001)。

关键数值与推荐

  • 2年泌尿刺激/梗阻领域MCID:SBRT组35.4%,MH-IMRT组33.7%(P=.68)。
  • 2年肠道领域MCID:SBRT组34.9%,MH-IMRT组43.8%(P=.03)。
  • 3+4级泌尿生殖不良事件:SBRT组0.6%,MH-IMRT组2.5%(P=.04)。
  • 3年DFS:MH-IMRT组92.1%(95%CI 88.9%-95.2%),SBRT组88.6%(95%CI 85.2%-92.1%)(单侧log-rank P<.001)。

临床怎么用

  • 对于中危局限期前列腺癌,SBRT可考虑作为改善肠道生活质量及减少泌尿生殖不良事件的选择。
  • 需向患者说明SBRT在无病生存方面未优于MH-IMRT,且3年DFS数值上MH-IMRT组更高。

局限性

  • 中位随访3.2年,不足以评估长期肿瘤学结局。
  • 研究纳入人群以白人为主(80%),亚洲人3%,黑人13%,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The treatment of prostate cancer with radiotherapy is evolving. How quickly radiotherapy can be delivered, and the relative risks and benefits of such a treatment, is of significant public interest. OBJECTIVE: To determine whether stereotactic body radiotherapy (SBRT) was superior to moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) in terms of patient-reported urinary irritative/obstructive and bowel quality of life and disease-free survival (DFS). DESIGN, SETTING, AND PARTICIPANTS: NRG-GU005 was a phase-3, international, open-label, randomized clinical trial. The study was activated on November 16, 2017, and closed to accrual on June 8, 2022. Date of last follow-up was October 13, 2024. There were 136 centers in Asia, Canada, Europe, and the United States that accrued patients to the study. Patients with localized prostate cancer, clinical stage T1-T2b with Gleason 3 + 4 (grade group 2) and prostate-specific antigen (PSA) level less than 20 ng/mL or Gleason 3 + 3 (grade group 1) and PSA level 10 to 20 ng/mL were eligible. Intended accrual of 692 patients provided reductions of 8% and 10% in minimal clinically important decline (MCID) frequency for urinary-irritative/obstructive and bowel domains of the Expanded Prostate Cancer Index Composite-26 Item (EPIC-26) instrument at 2 years and greater than 80% power to detect a hazard ratio of 0.62 in DFS. INTERVENTIONS: Patients were randomized 1:1 to receive SBRT (36.25 Gy in 5 fractions; n = 353) or MH-IMRT (70 Gy in 28 fractions or 60 Gy in 20 fractions; n =345). MAIN OUTCOMES AND MEASURES: Primary outcomes were the frequency of an MCID in the urinary irritative/obstructive and bowel domains of the EPIC-26 at 2 years and DFS at 3 years. RESULTS: A total of 698 patients were randomized. Median age was 68 years; 3% were Asian, 13% Black, and 80% White. Median follow-up was 3.2 years (range, 0-6.5). At 2 years, there was no significant difference in the urinary-irritative domain (35.4% vs 33.7%, P = .68). Urinary incontinence at 1 and 2 years after treatment and sexual function at 1 year after treatment favored SBRT. Fewer grade 3 + 4 genitourinary adverse events occurred in the SBRT vs MH-IMRT group (0.6% vs 2.5%, P = .04). There were significantly fewer MCIDs with SBRT vs MH-IMRT in the bowel domain (34.9% vs 43.8%, P = .03). At 3 years, DFS for MH-IMRT was 92.1% (95% CI, 88.9%-95.2%) vs 88.6% for SBRT (95% CI, 85.2%-92.1%) (1-sided log-rank P < .001). CONCLUSIONS AND RELEVANCE: Stereotactic body radiotherapy using a modest dose prescription improved multiple quality-of-life domains but was not superior to MH-IMRT in terms of DFS. The rate of PSA failure was not significantly improved in the SBRT vs MH-IMRT group. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03367702.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Ellis RJ, Pugh SL, Yu JB, et al. Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial. JAMA. 2026. PMID: 42593775. doi:10.1001/jama.2026.12627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。